enVVeno Medical Corp. Files Q2 2024 10-Q
Ticker: NVNO · Form: 10-Q · Filed: Jul 31, 2024 · CIK: 1661053
| Field | Detail |
|---|---|
| Company | Envveno Medical Corp (NVNO) |
| Form Type | 10-Q |
| Filed Date | Jul 31, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.00001, $30,000, $3 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, medical-devices, financials
TL;DR
enVVeno Medical Corp. dropped its Q2 10-Q. Check financials.
AI Summary
enVVeno Medical Corp. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Hancock Jaffe Laboratories, Inc., reported financial results for the second quarter and the first half of the year. Specific financial figures and operational details are contained within the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for enVVeno Medical Corp., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a medical device company, enVVeno Medical Corp. faces inherent risks related to product development, regulatory approvals, and market adoption.
Key Players & Entities
- enVVeno Medical Corp. (company) — Filer of the 10-Q
- Hancock Jaffe Laboratories, Inc. (company) — Former name of enVVeno Medical Corp.
- 20240630 (date) — End of the reporting period
- 20240731 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on July 31, 2024.
What was enVVeno Medical Corp. formerly known as?
enVVeno Medical Corp. was formerly known as Hancock Jaffe Laboratories, Inc.
What is the Standard Industrial Classification code for enVVeno Medical Corp.?
The Standard Industrial Classification code for enVVeno Medical Corp. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
In which state was enVVeno Medical Corp. incorporated?
enVVeno Medical Corp. was incorporated in Delaware (DE).
Filing Stats: 4,606 words · 18 min read · ~15 pages · Grade level 14.8 · Accepted 2024-07-31 16:05:39
Key Financial Figures
- $0.00001 — stered: Ticker Symbol Common Stock, $0.00001 par value The NASDAQ Stock Market LLC
- $30,000 — ent of a venous ulcer spends as much as $30,000 a year on wound care, and the total dir
- $3 billion — n the U.S. has been estimated to exceed $3 billion a year. 10 VenoValve The VenoValv
Filing Documents
- form10-q.htm (10-Q) — 409KB
- ex31-1.htm (EX-31.1) — 20KB
- ex31-2.htm (EX-31.2) — 20KB
- ex32.htm (EX-32) — 11KB
- 0001493152-24-029737.txt ( ) — 1885KB
- nvno-20240630.xsd (EX-101.SCH) — 15KB
- nvno-20240630_cal.xml (EX-101.CAL) — 30KB
- nvno-20240630_def.xml (EX-101.DEF) — 33KB
- nvno-20240630_lab.xml (EX-101.LAB) — 133KB
- nvno-20240630_pre.xml (EX-101.PRE) — 101KB
- form10-q_htm.xml (XML) — 161KB
Financial Statements (unaudited)
ITEM 1. Financial Statements (unaudited) 1 Condensed Balance Sheets as of June 30, 2024 and December 31, 2023 1 Condensed Statements of Operations for the three and six months ended June 30, 2024 and 2023 2 Condensed Statements of Changes in Stockholders' Equity for the six months ended June 30, 2024 and 2023 3 Condensed Statements of Cash Flows for the six months ended June 30, 2024 and 2023 4 Notes to Condensed Financial Statements 5
Management's Discussion and Analysis of Financial Condition and Results of Operations
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 9
Quantitative and Qualitative Disclosures About Market Risk
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 15
Controls and Procedures
ITEM 4. Controls and Procedures 15 PART II OTHER INFORMATION 16
Legal Proceedings
ITEM 1. Legal Proceedings 16
Risk Factors
ITEM 1A. Risk Factors 16
Unregistered Sales of Equity Securities and Use of Proceeds
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 16
Defaults Upon Senior Securities
ITEM 3. Defaults Upon Senior Securities 16
Mine Safety Disclosures
ITEM 4. Mine Safety Disclosures 16
Other Information
ITEM 5. Other Information 16
Exhibits
ITEM 6. Exhibits 17
Signatures
Signatures 18 i PART I – FINANCIAL INFORMATION ITEM 1 – Financial Statements ENVVENO MEDICAL CORPORATION CONDENSED BALANCE SHEETS (unaudited) June 30, 2024 December 31, 2023 (In thousands except par values, unless otherwise indicated) Assets Current Assets: Cash and cash equivalents $ 2,380 $ 3,620 Short-term investments 36,687 42,792 Prepaid expenses and other current assets 469 511 Total Current Assets 39,536 46,923 Property and equipment, net 252 334 Operating lease right-of-use assets, net 1,176 1,347 Security deposits and other assets 31 31 Total Assets $ 40,995 $ 48,635 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable, accrued expenses and other current liabilities $ 1,344 $ 1,033 Current portion of operating lease liabilities 351 338 Total Current Liabilities 1,695 1,371 Long-term operating lease liabilities 882 1,064 Total Liabilities 2,577 2,435 Commitments and Contingencies - - Stockholders' Equity: Preferred stock, par value $ 0.00001 , 10,000 shares authorized: no shares issued or outstanding - - Common stock, par value $ 0.00001 , 250,000 shares authorized, 13,330 and 13,317 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively - - Additional paid-in capital 178,402 176,236 Accumulated deficit ( 139,984 ) ( 130,036 ) Total Stockholders' Equity 38,418 46,200 Total Liabilities and Stockholders' Equity $ 40,995 $ 48,635 See Notes to these Unaudited Condensed Financial Statements 1 ENVVENO MEDICAL CORPORATION CONDENSED (unaudited) 2024 2023 2024 2023 For the Three Months Ended June 30, For the Six Months Ended June 30, 2024 2023 2024 2023 (In thousands, except per share data) Operating Expenses: Selling, general and administrative expenses 2,629 2,600 5,080 5,805 Research and development expenses 2,825 4,214 5,877 7,806 Loss from